EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Lurasidone response in bipolar type I depression with childhood trauma exposure

Hernan F Guillen-Burgos iD, Juan F Galvez-Florez, Sergio Moreno-López, Roger S McIntyre

International Journal of Neuropsychopharmacology · 2025

DOI: 10.1093/ijnp/pyaf020 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Neuropsychopharmacology, 2025. Verfasst von Hernan F Guillen-Burgos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Universidad El Bosque, Faculty of Medicine, Center for Clinical and Translational Research, Bogota DC, Colombia. Hauptthemen laut MEDLINE: Lurasidone Hydrochloride, Bipolar Disorder, Antipsychotic Agents, Outcome Assessment, Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidad El Bosque and Universidad Simon Bolivar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Childhood trauma (CT) worse the course of bipolar disorder (BD) and negatively impacts treatment outcomes. Despite the recognized influence of CT on clinical trajectories, limited evidence exists on how it affects specific pharmacological responses in BD.

Objective

This study aimed to investigate the effectiveness of lurasidone in BD type I depression, with a focus on how CT exposure impacts treatment response and remission.

Design

A multisite, observational, prospective, comparative effectiveness study over an 8-week period was conducted.

Setting

A multisite in 4 clinical research sites in Colombia.

Participants

A total of 84 adults with BD type I depression were enrolled (lurasidone = 41, lurasidone with lithium = 43).

Intervention

Over an 8-week period, 41 participants were assigned to the lurasidone arm and 43 to the lurasidone plus lithium arm. Exposure Childhood trauma exposure was measured with the Childhood Trauma Questionnaire-Short Form. BD with CT (n = 40) and BD without CT (n = 44) were included. Main outcome and measures The primary outcome was changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Secondary outcomes included changes in Clinical Global Impression-Bipolar depression severity scores and responder rates.

Results

Bipolar disorder with CT exposure demonstrated a smaller mean reduction in MADRS scores compared to those without CT exposure for both treatments (monotherapy: Least Square (LS) −3.4, 95% CI, −6.03 to −0.76, P = .013; combination therapy: LS −3.1, 95% CI, −5.36 to −0.63, P = .014). The presence of CT exposure, particularly physical abuse (PA), was associated with poorer response rates. Notably, lurasidone in combination with lithium showed superior outcomes compared to monotherapy, although effectiveness was attenuated in participants with documented CT exposure.

Conclusions

This study provides real-world evidence suggesting that CT exposure may modify treatment response in BD type I depression. Our findings underscore the importance of CT screening to guide personalized treatment strategies. Relevance This study provides evidence that CT, particularly PA, attenuates the antidepressant effects of lurasidone in BD type I depression, leading to lower response and remission rates in both monotherapy and combination therapy with lithium. These findings underscore the clinical importance of screening for CT in BD to guide personalized treatment strategies. Identifying trauma history may help clinicians optimize treatment selection, considering the potential need for combination pharmacotherapy and adjunctive trauma-focused psychotherapeutic interventions to improve outcomes in this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lurasidone HydrochlorideBipolar DisorderAntipsychotic AgentsOutcome Assessment, Health CareHumansMaleFemaleAdultMiddle AgedProspective StudiesDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

bipolar disorderchildhood traumalithiumlurasidonetreatment response

Substanzen

Lurasidone HydrochlorideAntipsychotic Agents

Autor:innen und Institutionen

  • Universidad El Bosque, Faculty of Medicine, Center for Clinical and Translational Research, Bogota DC, Colombia.
  • Universidad Simon Bolivar, Center for Clinical and Translational Research, Barranquilla, Colombia.
  • Pontificia Universidad Javeriana, Department of Psychiatry and Mental Health, Hospital Universitario San Ignacio, Bogota DC, Colombia.
  • Universidad de Los Andes, Faculty of Medicine, Bogota DC, Colombia.
  • Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Hernan F Guillen-Burgos

Förderung

  • Universidad El Bosque and Universidad Simon Bolivar

Zitieren

APA

Guillen-Burgos, H. F., Galvez-Florez, J. F., Moreno-López, S., & McIntyre, R. S. (2025). Lurasidone response in bipolar type I depression with childhood trauma exposure. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf020

Vancouver

Guillen-Burgos HF, Galvez-Florez JF, Moreno-López S, McIntyre RS. Lurasidone response in bipolar type I depression with childhood trauma exposure. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf020

BibTeX
@article{GuillenBurgos2025,
  author = {Guillen-Burgos, Hernan F and Galvez-Florez, Juan F and Moreno-López, Sergio and McIntyre, Roger S},
  title = {Lurasidone response in bipolar type I depression with childhood trauma exposure},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  doi = {10.1093/ijnp/pyaf020}
}
Kostenlos starten →